491 related articles for article (PubMed ID: 25738199)
1. ¹⁸F-NaF PET/CT and ¹¹C-Choline PET/CT for the initial detection of metastatic disease in prostate cancer: overview and potential utilization.
Koo PJ; David Crawford E
Oncology (Williston Park); 2014 Dec; 28(12):1057-62, 1064-5. PubMed ID: 25738199
[TBL] [Abstract][Full Text] [Related]
2. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer.
Wondergem M; van der Zant FM; van der Ploeg T; Knol RJ
Nucl Med Commun; 2013 Oct; 34(10):935-45. PubMed ID: 23903557
[TBL] [Abstract][Full Text] [Related]
3. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
BJU Int; 2012 Nov; 110(10):1501-6. PubMed ID: 22502982
[TBL] [Abstract][Full Text] [Related]
4. Bone metastases from prostate cancer: 18F-fluoride PET/CT in a patient with discordant bone scintigraphy and 11C-choline PET/CT.
Garcia G; Riera E; Valls E; Soler M; Bassa P; Moragas M; Lomeña F
Clin Nucl Med; 2013 Feb; 38(2):120-4. PubMed ID: 23334127
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic relevance of choline-PET / CT in patients with prostate cancer].
Zengerling F; Schrader AJ; Schrader M; Jentzmik F
Aktuelle Urol; 2012 Jan; 43(1):49-54. PubMed ID: 21769763
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT.
Beheshti M; Rezaee A; Geinitz H; Loidl W; Pirich C; Langsteger W
J Nucl Med; 2016 Oct; 57(Suppl 3):55S-60S. PubMed ID: 27694173
[No Abstract] [Full Text] [Related]
7. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
8. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
9. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading.
Langsteger W; Balogova S; Huchet V; Beheshti M; Paycha F; Egrot C; Janetschek G; Loidl W; Nataf V; Kerrou K; Pascal O; Cussenot O; Talbot JN
Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):448-57. PubMed ID: 21738117
[TBL] [Abstract][Full Text] [Related]
10. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates.
Krause BJ; Souvatzoglou M; Treiber U
Urol Oncol; 2013 May; 31(4):427-35. PubMed ID: 21388835
[TBL] [Abstract][Full Text] [Related]
11. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
[TBL] [Abstract][Full Text] [Related]
12. Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice.
Bastawrous S; Bhargava P; Behnia F; Djang DS; Haseley DR
Radiographics; 2014; 34(5):1295-316. PubMed ID: 25208282
[TBL] [Abstract][Full Text] [Related]
13. The role of PET/CT and current challenges in prostate cancer management.
Lindholm P; Seppänen M; Minn H
Nucl Med Commun; 2009 May; 30(5):325. PubMed ID: 19421025
[No Abstract] [Full Text] [Related]
14. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
Tuncel M; Souvatzoglou M; Herrmann K; Stollfuss J; Schuster T; Weirich G; Wester HJ; Schwaiger M; Krause BJ
Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT.
Dyrberg E; Larsen EL; Hendel HW; Thomsen HS
Acta Radiol; 2018 Sep; 59(9):1119-1125. PubMed ID: 29313360
[TBL] [Abstract][Full Text] [Related]
16. The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer.
Kulshrestha RK; Vinjamuri S; England A; Nightingale J; Hogg P
J Nucl Med Technol; 2016 Dec; 44(4):217-222. PubMed ID: 27634981
[TBL] [Abstract][Full Text] [Related]
17.
Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
[TBL] [Abstract][Full Text] [Related]
18. 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer.
Ceci F; Castellucci P; Graziani T; Schiavina R; Chondrogiannis S; Bonfiglioli R; Costa S; Virgolini IJ; Rubello D; Fanti S; Colletti PM
Clin Nucl Med; 2015 May; 40(5):e265-70. PubMed ID: 25783519
[TBL] [Abstract][Full Text] [Related]
19. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
[TBL] [Abstract][Full Text] [Related]
20. Prospective comparative study of
Fonager RF; Zacho HD; Langkilde NC; Fledelius J; Ejlersen JA; Hendel HW; Haarmark C; Moe M; Mortensen JC; Jochumsen MR; Petersen LJ
Acta Oncol; 2018 Aug; 57(8):1063-1069. PubMed ID: 29447047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]